An analysis found that MS patients on a less frequent anti-CD20 therapy dosing schedule do not have more relapses or show ...

An FDA-approved multiple sclerosis drug that requires 2.5 hours for the first infusion and 3.5 hours for subsequent doses might be able to shorten its duration to 10 minutes, its maker said July 14.

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS ...

A new LOCAL online community built for you. Click now to see all the available groups. BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of ...

The blogger Trevis Gleason explores long-term effects of corticosteroid use in managing multiple sclerosis, and what everyone with MS should know.

Roche Holdings AG's RHHBY Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with ...

Drs Anne Cross and Scott Newsome discuss new horizons in MS treatment strategies, including the TREAT-MS trial and shared ...

How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...

On December 28, 2022, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), a disease-modifying therapy (DMT) to treat relapsing forms of multiple sclerosis (RMS) in adults, ...